BioAffinity Technologies (BIAF) announced that the China National Intellectual Property Administration has issued a notification of patent grant for the company’s novel composition and method for selectively killing cancer by targeting the CD320 and LRP2 receptors. The newly allowed Chinese patent, titled “Compositions and Methods for Treating Cancer,” covers siRNAs and their use in cancer treatment, similar to its recent U.S. patent. The company is exploring topical application for skin cancers.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIAF:
- bioAffinity Receives Nasdaq Non-Compliance Notice
- BioAffinity gets U.S. patent for novel broad spectrum cancer therapies
- bioAffinity Technologies Enters Sales Agreement with WallachBeth
- BioAffinity Technologies appoints Dr. Gordon Downie as Chief Medical Officer
- bioAffinity Technologies Sets 2025 Annual Meeting Date